pharma news

News

AZ's Etcamah falls short in first-line breast cancer trial

A week after getting FDA approval for frontline breast cancer treatment, AstraZeneca's Etcamah missed the mark in a trial aiming to expand its label.

News

Just Don't in capital white letters on side of building

Resistance grows to Recordati's private equity takeover

The offer for Recordati by private equity firms CVC and GBL undervalues the company and is unfair to minority shareholders, claims activist investor.

News

Scholar Rock gets first drug approval as FDA okays Isembyld

Scholar Rock has won its first product approval, on its second attempt, as the FDA gives a green light to its spinal muscular atrophy drug Isembyld.

News

Novo Nordisk rebrands as Novo as new CEO charts turnaround

Embroiled in a fight to retain market share in weight loss and diabetes therapies, Novo Nordisk has rebranded and launched a new corporate culture.

News

Hengrui gets world-first okay for platelet drug hetrombopag

Hengrui's oral TPO agonist, hetrombopag, is the first in the class to be approved for thrombocytopenia caused by chemotherapy for solid tumours.

News

Andy Plump to step down as Takeda's R&D chief

Andy Plump, credited with a 'soup-to-nuts' overhaul of Takeda's R&D in more than a decade of leadership at the division, has announced his retirement.

AZ's Etcamah falls short in first-line breast cancer trial

Resistance grows to Recordati's private equity takeover

Scholar Rock gets first drug approval as FDA okays Isembyld

Novo Nordisk rebrands as Novo as new CEO charts turnaround

Hengrui gets world-first okay for platelet drug hetrombopag

Andy Plump to step down as Takeda's R&D chief

Getting predictive technologies to patients, with Concr

Discover a new era of healthcare panel engagement: Grounded ...

pharma news

Editor's Picks